Tolerance and efficacy of rituximab and changes in serum B cell biomarkers in patients with systemic complications of primary Sjögren's syndrome
R Seror, C Sordet, L Guillevin, E Hachulla… - Annals of the …, 2007 - ard.bmj.com
Objective: To investigate the safety and efficacy of rituximab (RTX) for systemic symptoms in
patients with primary Sjögren's syndrome (pSS), and changes in B cell biomarkers. Patients …
patients with primary Sjögren's syndrome (pSS), and changes in B cell biomarkers. Patients …
[PDF][PDF] Tolerance and efficacy of rituximab and changes in serum B cell biomarkers in patients with systemic complications of primary Sjögren's syndrome
Ann Rheum Dis, 2007 - researchgate.net
Objective: To investigate the safety and efficacy of rituximab (RTX) for systemic symptoms in
patients with primary Sjögren's syndrome (pSS), and changes in B cell biomarkers. Patients …
patients with primary Sjögren's syndrome (pSS), and changes in B cell biomarkers. Patients …
Tolerance and efficacy of rituximab and changes in serum B cell biomarkers in patients with systemic complications of primary Sjögren's syndrome.
R Seror, C Sordet, L Guillevin, E Hachulla… - Annals of the …, 2006 - europepmc.org
Tolerance and efficacy of rituximab and changes in serum B cell biomarkers in patients with
systemic complications of primary Sjögren's syndrome. - Abstract - Europe PMC Sign in | Create …
systemic complications of primary Sjögren's syndrome. - Abstract - Europe PMC Sign in | Create …
[引用][C] Tolerance and efficacy of rituximab and changes in serum B cell biomarkers in patients with systemic complications of primary Sjögren's syndrome
R SEROR, C SORDET… - Annals of the …, 2007 - pascal-francis.inist.fr
Tolerance and efficacy of rituximab and changes in serum B cell biomarkers in patients with
systemic complications of primary Sjögren's syndrome CNRS Inist Pascal-Francis CNRS …
systemic complications of primary Sjögren's syndrome CNRS Inist Pascal-Francis CNRS …
Tolerance and efficacy of rituximab and changes in serum B cell biomarkers in patients with systemic complications of primary Sjögren's syndrome
R Seror, C Sordet, L Guillevin… - Annals of the …, 2007 - search.proquest.com
Objective: To investigate the safety and efficacy of rituximab (RTX) for systemic symptoms in
patients with primary Sjögren's syndrome (pSS), and changes in B cell biomarkers. Patients …
patients with primary Sjögren's syndrome (pSS), and changes in B cell biomarkers. Patients …
Tolerance and efficacy of rituximab and changes in serum B cell biomarkers in patients with systemic complications of primary Sjögren's syndrome
R Seror, C Sordet, E Hachulla, C Masson… - Annals of the …, 2006 - ard.bmj.com
Objective. To investigate the safety and efficacy of rituximab (RTX) for systemic symptoms in
patients with primary Sjogren's Syndrome (pSS) and change in B-cell biomarkers. Patients …
patients with primary Sjogren's Syndrome (pSS) and change in B-cell biomarkers. Patients …
[HTML][HTML] Tolerance and efficacy of rituximab and changes in serum B cell biomarkers in patients with systemic complications of primary Sjögren's syndrome
R Seror, C Sordet, L Guillevin, E Hachulla… - Annals of the …, 2007 - ncbi.nlm.nih.gov
Tolerance and efficacy of rituximab and changes in serum B cell biomarkers in patients with
systemic complications of primary Sjögren's syndrome - PMC Back to Top Skip to main content …
systemic complications of primary Sjögren's syndrome - PMC Back to Top Skip to main content …
Tolerance and efficacy of rituximab and changes in serum B cell biomarkers in patients with systemic complications of primary Sjögren's syndrome
R Seror, C Sordet, L Guillevin… - Annals of the …, 2007 - pubmed.ncbi.nlm.nih.gov
Objective To investigate the safety and efficacy of rituximab (RTX) for systemic symptoms in
patients with primary Sjögren's syndrome (pSS), and changes in B cell biomarkers. Patients …
patients with primary Sjögren's syndrome (pSS), and changes in B cell biomarkers. Patients …
[PDF][PDF] Tolerance and efficacy of rituximab and changes in serum B cell biomarkers in patients with systemic complications of primary Sjögren's syndrome
Ann Rheum Dis, 2007 - academia.edu
Objective: To investigate the safety and efficacy of rituximab (RTX) for systemic symptoms in
patients with primary Sjögren's syndrome (pSS), and changes in B cell biomarkers. Patients …
patients with primary Sjögren's syndrome (pSS), and changes in B cell biomarkers. Patients …
[引用][C] Tolerance and efficacy of rituximab and changes in serum B cell biomarkers in patients with systemic complications of primary Sjogren's syndrome
R SEROR - Ann Rheum Dis., 2007 - cir.nii.ac.jp
Tolerance and efficacy of rituximab and changes in serum B cell biomarkers in patients with
systemic complications of primary Sjogren's syndrome | CiNii Research CiNii 国立情報学 …
systemic complications of primary Sjogren's syndrome | CiNii Research CiNii 国立情報学 …